Product ID: SQMIG35H2166
Report ID:
SQMIG35H2166 |
Region:
Global |
Published Date: April, 2024
Pages:
219
|
Tables:
59 |
Figures:
76
In 2022, North America dominated the market and contributed 38.97% of total revenue. The increase in cardiovascular diseases and injuries is to blame for this. In addition, rising levels of healthcare spending and rising patient awareness in this region are the other variables that contribute to the high share. According to the CDC, heart disease will be one of the leading causes of death in the United States in 2022, killing 659,000 people a year, or 1 in every 4 fatalities.
The market is anticipated to grow at the fastest rate in Asia Pacific, 3.9%, during the anticipated period. Some of the main drivers of the expansion are the growing elderly population, the large chronic disease population, and expanding economy. The region that delivers the most API and crude heparin is Asia Pacific, as well. Local businesses, like Pharma Life Sciences, benefit from this. Generic versions of pharmaceuticals whose patents have expired are being produced locally at a reasonable price.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35H2166